The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.

Exclusion Criteria

• •Patient with documented kalemia ≥ 5mmol/L in the last 15 days;
• •Patient undergoing mineralocorticoid receptor antagonism or with a formal indication to receive this treatment;
• •Bicarbonate blood level \<20mmol/L with or without documented supplementation in the last 15 days.
• •Indication for a combination of ACE inhibitor and sartan (each of which is authorized separately);
• •Patient under another potassium sparing diuretics;
• •Patient under digoxine;
• •Sodium polystyrene sulfonate contraindication;
• •Known hypersensitivity or allergy to eplerenone and its excipients;
• •Patient with severe hepatic impairment (Child-Pugh Class C);
• •Patient under CYP3A4 inhibitor;
• •know intolerance to Galactose, a Lapp lactase deficiency or galactose malabsorption syndrome;
• •Patient participating in other interventional research;
• •Woman with a desire of pregnancy within 15 months;
• •Woman of childbearing age without effective contraception;
• •Persons referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code :
• •Pregnant women, parturient women or nursing mothers ;
• •Adult person subject to a legal protection measure (guardianship, curator, judicial safeguard);
• •Adults person who is unable to give consent and who is not subject to a legal protection measure;
• •Persons deprived of their liberty by a judicial or administrative decision;
• •Persons subject to psychiatric care pursuant to articles L. 3212-1 and L. 3213-1.